QI
ATYR

Quotient Investors’s aTyr Pharma ATYR Stock Holding History

Quotient Investors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$112K Hold
1,586
– – 0.08% 138
2017
Q2 		$77K Hold
1,586
– – 0.05% 142
2017
Q1 		$78K Hold
1,586
– – 0.05% 167
2016
Q4 		$48K Hold
1,586
– – 0.03% 172
2016
Q3 		$71K Buy
+1,586
New +$68.5K 0.05% 170

Other funds holding ATYR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Quotient Investors's ATYR Position: Q3 2017 in Review

Quotient Investors held its aTyr Pharma (ATYR) position steady in Q3 2017 at 1,586 shares worth $112K. The position accounts for 0.08% of the portfolio, ranked #138.

Quotient Investors first reported a position in ATYR in Q3 2016 and has held it in 5 quarters since. 39 funds tracked by Wall St. Rank hold ATYR as of Q3 2017.

  • Quotient Investors held 1,586 shares of aTyr Pharma worth $112K as of Q3 2017.
  • Quotient Investors left its aTyr Pharma share count unchanged in Q3 2017.
  • aTyr Pharma made up 0.08% of Quotient Investors's portfolio in Q3 2017, its #138 holding.
  • Quotient Investors first reported a position in aTyr Pharma in Q3 2016 and has held it in 5 quarters since.
  • 39 funds tracked by Wall St. Rank held aTyr Pharma as of Q3 2017.

Based on Quotient Investors's 13F filing for Q3 2017, filed 18 Oct 2017.